| • |
The PolyArginine Treated vEiN grafTs (PATENT) study was Lumen's first clinical study |
| • |
This Lumen sponsored clinical study was a placebo-controlled, double-blinded, and randomized Phase I/IIA study performed at Toronto General Hospital (TGH) |
| • |
TGH is home to the largest open-heart surgery center in Canada and has the best clinical study outcomes of cardiovascular surgery in the country |
| • |
Study Design: Patients requiring multiple-vein CABG had comparative treatment of LT-1951 and placebo. |
| • |
Phase I Study successfully completed |
| • |
Phase II Study – 20 patients treated and evaluated |
| • |
Clear signal (P < 0.01) for treatment reducing the rate of graft failure at 1 month |
| • |
Need for vehicle optimization identified |
